Clinical Trials

366 enrolled

Breast Neoplasms

NCT06211881 2024-01-18

Chi-GVM Regimen for the Treatment of R/R PTCL

Phase NA Unknown

50 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02465736 2024-01-16

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

610 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03620032 2023-12-06

DIPG

54 enrolled

CNS

Diffuse Intrinsic Pontine Glioma

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

123 enrolled

Breast Cancer Metastatic

NCT04304352 2023-06-28

VEX

162 enrolled

Advanced Breast Cancer

NCT00431704 2023-03-24

VinCaT

39 enrolled

Breast Neoplasms

NCT05747326 2023-02-28

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Breast Neoplasms

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

45 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

HER2-negative Breast Cancer

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT02607215 2022-04-20

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

84 enrolled

Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT05131841 2021-11-23

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Phase 4 Unknown

60 enrolled

Breast Neoplasms

NCT02448797 2021-07-20

EVIDENCE

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Breast Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04665986 2020-12-14

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

50 enrolled

Breast Neoplasms

NCT02977169 2020-11-13

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03270007 2020-10-28

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Phase 4 Unknown

304 enrolled

Primary Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Hormone Receptor Positive Advanced Breast Cancer

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

20 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04307147 2020-03-13

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

316 enrolled

Breast Neoplasms

NCT04302441 2020-03-10

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

550 enrolled

Breast Neoplasms

NCT04143906 2019-10-30

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Breast Neoplasms

NCT04021992 2019-08-06

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

48 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03997539 2019-06-25

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

256 enrolled

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Phase NA Unknown

48 enrolled

HER2 Positive Breast Cancer

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

184 enrolled

Triple Negative Breast Neoplasms

NCT03703427 2018-10-12

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Pathologic Residual Cancer Cells

NCT03656393 2018-09-04

RCTACSCNSCLC

48 enrolled

NSCLC

NCT03188159 2018-03-29

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

36 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Phase 2/3 Unknown

Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

300 enrolled

Breast Neoplasms, Genetic Predisposition to Disease

NCT02489409 2017-07-17

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

120 enrolled

Breast Neoplasms

NCT02144194 2017-02-09

TNM

65 enrolled

Breast Neoplasms

NCT03006614 2017-01-16

PERS

320 enrolled

Breast Neoplasms

NCT02579564 2016-10-21

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

134 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01683175 2016-10-20

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

94 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02897986 2016-09-13

PROVIN

Phase 1 Unknown

54 enrolled

Tumor-Agnostic

Neoplasms

NCT02665702 2016-01-28

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

76 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02544243 2015-09-09

Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer

Breast Neoplasms

NCT01843647 2015-07-15

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Carcinoma, Non-Small-Cell Lung

NCT02319577 2014-12-18

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02281708 2014-11-03

Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma

1,012 enrolled

Lung Neoplasms, Recurrence

NCT02223611 2014-08-22

S1VSNP